2 (Amended). A process according to claim 1 in which the emulsifier is a polyvinyl alcohol; [the antifoam agent is a] said aqueous phase further contains 0.1 to 1.0 wt. % of a polydimethyl siloxane; the ratio of clomazone to PMPPI is 4.5:1 to 4.7:1; the polyamine is a mixture of TETA and HDA in which the ratio of TETA to HDA is 3:1 to 1:3; the microcapsules are cured at 45° to 50° C. for 4 to 5 hours and have an average size of 5 to 30 microns.

4 (Amended). A process according to claim 1 in which the emulsifier is a polyvinyl alcohol; [the antifoam agent is a] said aqueous phase further contains 0.1 to 1.0 wt.% of a polydimethyl siloxane; the ratio of clomazone to PMPPI is 4.5:1 to 4.7:1; the polyamine is a mixture of DETA and HDA in which the ratio of DETA to HDA is 3:1 to 1:3; the microcapsules are cured at 45° to 50° C. for 4 to 5 hours and have an average size of 5 to 30 microns.

6 (Amended). A process according to claim 1 in which the emulsifiers are a polyvinyl alcohol [and, optionally a sodium salt of sulfonated naphthalene condensate]; [the antifoam agent is a] said aqueous phase further comprises 0.1 to 1.0 wt.% of a polydimethyl siloxane; the ratio of clomazone to PMPPI is 4.5:1 to 4.7:1; the polyamine is DETA, the microcapsules are cured at 45° to 50° C. for 4 to 5 hours and have an average size of 5 to 30 microns.

28 (Amended). The herbicidal formulation of claim 27, wherein the formulation has a 100 mesh wet screen analysis of greater than 99.95%.

37 (Amended). A microencapsulated clomazone formulation comprising a polyurea shell, whereby said polyurea shell substantially reduces the volatility of clomazone.

~~39~~ 38 (Amended). The microencapsulated clomazone formulation of claim 37, wherein said polyurea shell is formed by interfacial polymerization of polymethylene polyphenyl isocyanate and a poly functional amine.

~~40~~ 39 (Amended). The microencapsulated clomazone formulation of claim ~~39~~ 38, wherein the polyfunctional amine is selected from the group consisting of ethylenediamine (EDA), diethyltriamine (DETA), triethylenetetramine (TETA), and 1,6-hexanediamine (HDA), with the proviso that (EDA) is used only in a mixture.

END

REMARKS

Amendments to the Claims

Claims 2, 4, 6, 28, 37, 39, and 40 are amended herein and claim 38 is cancelled. Claims 2, 4 and 6 have been amended to address an antecedent concern. The amendments to such claims are fully supported, for example, by the originally issued claims. Claim 28 has been amended for grammatical reasons. Claim 37 is amended so as to insert claim 38 thereinto, as well as to insert the word "formulation". Support for the word "formulation" can be found throughout the specification, e.g., at col. 1, line 6. Claims 39 and 40 have been amended to reflect a change in dependency and also to add the word "formulation". It is respectfully